Anti-endotoxin monoclonal antibodies are protective against hepatic ischemia/reperfusion injury in steatotic mice

American Journal of Transplantation

Volumn 4, Issue 10, 2004, Pages 1567-1573

  Fiorini, Ryan N ^a   Shafizadeh, Stephen F ^a   Polito, Carmen ^a   Rodwell, David W ^a   Cheng, Gang ^a   Evans, Zachary ^a   Wan, Chidan ^a   Beiden, Sarah ^a   Haines, Julia K ^a   Birsner, Jennifer ^a   Lewin, David ^a   Wasiluk, Karen R ^b   Dunn, David L ^b   Schmidt, Michael G ^a   Chavin, Kenneth D ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Antibody; Endotoxin; Liver; Steatosis

Indexed keywords

ADENOSINE TRIPHOSPHATE; ENDOTOXIN; ENDOTOXIN ANTIBODY; LIPOPOLYSACCHARIDE MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; ATTENUATION; CELL PROTECTION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOSE TIME EFFECT RELATION; FATTY LIVER; LEPTIN GENE; LIVER ISCHEMIA; LIVER TRANSPLANTATION; MOUSE; MUTATOR GENE; NONHUMAN; OBESITY; PRIORITY JOURNAL; REPERFUSION INJURY; SPONTANEOUS MUTATION; STEATOSIS; SURVIVAL;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; ENDOTOXINS; FATTY LIVER; LIVER; MALE; MICE; MICE, OBESE; REPERFUSION INJURY;

EID: 4744374657     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00549.x     Document Type: Article

References (44)

1. D'Alessandro AM, Kalayoglu M, Sollinger HW et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 1991; 51: 157-163.
2. Marsman WA, Wiesner RH, Rodriguez L et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996; 62: 1246-1251.
3. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001; 21: 105-113.
4. Salizzoni M, Franchello A, Zamboni F et al. Marginal grafts: finding the correct treatment for fatty livers. Transpl Int 2003; 16: 486-493.
5. Tsoulfas G, Takahashi Y, Ganster RW et al. Activation of the lipopolysaccharide signaling pathway in hepatic transplantation preservation injury. Transplantation 2002; 74: 7-13.
6. Kellogg TA, Weiss CA, Johnston JW 3rd, Wasiluk KR, Dunn DL. Antiendotoxin agents share molecular homology within their lipopolysaccharide binding domains. J Surg Res 1999; 85: 136-141.
7. van Goor H, Rosman C, Grond J et al. Translocation of bacteria and endotoxin in organ donors. Arch Surg 1994; 129: 1063-1066.
8. Pillay SP, Moore TD, Lynch SV et al. Endotoxin levels in adult liver donors. Aust N Z J Surg 1994; 64: 615-617.
9. Miyata T, Todo S, Imventarza O et al. Endogenous endotoxemia during orthotopic liver transplantation in dogs. Transplant Proc 1989; 21: 3861-3862.
10. Albillos A, de la Hera A, Gonzalez M et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-217.
11. Arai M, Mochida S, Ohno A, Arai S, Fujiwara K. Selective bowel decontamination of recipients for prevention against liver injury following orthotopic liver transplantation: evaluation with rat models. Hepatology 1998; 27: 123-127.
12. Bhattacharjee AK, Opal SM, Palardy JE et al. Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis. J Infect Dis 1994; 170: 622-629.
13. Stephens R, Hamilton-Davies C. Update on antiendotoxin therapies. Hosp Med 2000; 61: 254-258.
14. Pollack M, Hunter KW, inventors; Centocor, Inc., assignee. Monoclonal antibodies reactive with endotoxin core. US patent 5, 057, 598. 1991 October 15.
15. Priest BP, Brinson DN, Schroeder DA, Dunn DL. Treatment of experimental gram-negative bacterial sepsis with murine monoclonal antibodies directed against lipopolysaccharide. Surgery 1989; 106: 147-154.
16. Chavin KD, Yang S, Lin HZ et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274: 5692-5700.
17. Fujiwara H, Kira K, Asakawa S et al. The application of the endotoxin test for globulin and other blood products. Yakugaku Zasshi 1999; 119: 451-455.
18. Asakawa S, Fujiwara H, Naito S et al. Application of the Limulus test for practical quality control on endotoxin content in commercial human serum albumin (HSA) products. In comparison with the rabbit pyrogen test. Yakugaku Zasshi 1994; 114: 888-893.
19. Naito S, Fujiwara H, Asakawa S et al. Application of the limulus amebocyte lysate test for measurement of endotoxin in the therapeutic human plasma protein fraction. Comparison with the rabbit pyrogen test. Yakugaku Zasshi 1992; 112: 551-556.
20. Army Medical Museum (US). Luna LG (ed). Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology, 3rd edn. New York: McGraw-Hill Co, 1968.
21. Preece A. A Manual for Histologic Technicians, 3rd edn. Boston: Carolina Press, 1985.
22. Neil DA, Hubscher SG. Are parenchymal changes in early post-transplant biopsies related to preservation-reperfusion injury or rejection? Transplantation 2001; 71: 1566-1572.
23. Means TK, Golenbock DT, Fenton MJ. The biology of Toll-like receptors. Cytokine Growth Factor Rev 2000; 11: 219-232.
24. Lemasters JJ. V. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis. Am J Physiol 1999; 276: G1-G6.
25. Jaeschke H, Lemasters JJ. Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology 2003; 125: 1246-1257.
26. Rudiger HA, Graf R, Clavien PA. Liver ischemia: apoptosis as a central mechanism of injury. J Invest Surg 2003; 16: 149-159.
27. Hamada E, Nishida T, Uchiyama Y et al. Activation of Kupffer cells and caspase-3 involved in rat hepatocyte apoptosis induced by endotoxin. J Hepatol 1999; 30: 807-818.
28. Levinsky NG. Organ donation by unrelated donors: N Engl J Med 2000; 343: 430-432.
29. Imber CJ, St Peter SD, Manda A, Friend PJ. Hepatic steatosis and its relationship to transplantation. Liver Transpl 2002; 8: 415-423.
30. Tekin K, Imber CJ, Atli M et al. A simple scoring system to evaluate the effects of cold ischemia on marginal liver donors. Transplantation 2004; 77: 411-416.
31. Dunn DL, Priest BP, Condie RM. Protective capacity of polyclonal and monoclonal antibodies directed against endotoxin during experimental sepsis. Arch Surg 1988; 123: 1389-1393.
32. Burd RS, Battafarano RJ, Cody CS et al. Anti-endotoxin monoclonal antibodies inhibit secretion of tumor necrosis factor-alpha by two distinct mechanisms. Ann Surg 1993; 218: 250-259.
33. Billiar TR, West MA, Hyland BJ et al. Murine monoclonal antibody directed against lipopolysaccharide (LPS) inhibits Kupffer cell activation by endotoxin in vitro. Prog Clin Biol Res 1988; 264: 367-372.
34. Ziegler EJ, Fisher CJ Jr, Sprung CL et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324: 429-436.
35. Bud O, Coiling M, von Frankenberg M et al. Intramucosal pH and serum endotoxin concentrations as early predictive parameters for primary nonfunction after experimental liver transplantation. Transplant Proc 2000; 32: 2537-2538.
36. Llovet JM, Rodriguez-Iglesias P, Moitinho E et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. J Hepatol 1997; 26: 88-95.
37. Zipfel A, Schenk M, You MS et al. Endotoxemia in organ donors: graft function following liver transplantation. Transpl Int 2000; 13 (Suppl. 1): S286-S287.
38. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994; 121: 1-5.
39. Ziegler EJ, McCutchan JA, Fierer J et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307: 1225-1230.
40. Pollack M, Raubitschek AA, Larrick JW. Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides. J Clin Invest 1987; 79: 1421-1430.
41. Nanji AA, Khettry U, Sadrzadeh SM, Yamanaka T. Severity of liver injury in experimental alcoholic liver disease. Correlation with plasma endotoxin, prostaglandin E2, leukotriene B4, and thromboxane B2. Am J Pathol 1993; 142: 367-373.
42. McCord JM. Superoxide radical: controversies, contradictions, and paradoxes. Proc Soc Exp Biol Med 1995; 209: 112-117.
43. McClain D, Schmidt J, Diehl AM. Cytokines and alcoholic liver disease. Semin Liver Dis 1993; 13: 170-182.
44. Deaciuc IV, D'ouza NB, de Villiers WJ et al. Inhibition of caspases in vivo protects the rat liver against alcohol-induced sensitization to bacterial lipopolysaccharide. Alcohol Clin Exp Res 2001; 25: 935-943.